Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common cause of chronic liver disease worldwide. Its rising prevalence has reflected that of obesity and other metabolic comorbidities such as type 2 diabetes mellitus, highlighting their roles as major risk factors. Metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis represents the most advanced stage of disease. Currently, no MASH-targeted therapy can be recommended in MASH-related cirrhosis, with no pharmacotherapy shown to be effective in regressing fibrosis once cirrhosis is established. Although cirrhosis has long been viewed as irreversible, evidence increasingly shows that regression is possible once the underlying precipitant of liver injury is removed. Owing to greater weight loss and metabolic improvements, bariatric surgery may achieve histological regression of MASH-related cirrhosis where pharmacological therapies have not; however, the evidence remains limited. This review examines whether bariatric surgery can facilitate regression of histologically confirmed MASH-related cirrhosis, presenting the current evidence for histological regression, comparing surgery with other available MASLD treatments, and examining the safety of surgery in this population.
No takes yet. Share an insight, caveat, or question.
Egan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: